Scientists test Two-Pronged attack on rare digestive cancers
NCT ID NCT04750954
Summary
This early-stage trial is testing whether adding an experimental pill called peposertib to a targeted radiation treatment (lutetium Lu 177 dotatate) is safe and effective for patients with advanced neuroendocrine tumors in the digestive system. The main goal is to find the best dose of the combination and understand its side effects. Researchers hope the two drugs working together will kill more cancer cells than the radiation treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.